Hydroxytyrosol composition and application thereof in anti-aging products

Abstract

The invention belongs to the technical field of nutritional compositions and cosmetics, and particularly relates to a hydroxytyrosol composition and application thereof in anti-aging products. The hydroxytyrosol composition disclosed by the invention is prepared from pyrroloquinoline quinone and hydroxytyrosol. The extracellular matrix (ECM) is a core basis for maintaining the structure and form of the skin, the collagen is a core component of the ECM, and the hydroxyproline is a characteristic amino acid of the collagen; the TGF-beta1 and the MMP-1 are used as key factors of senescence-related secretory phenotypes to regulate and control ECM remodeling and skin senescence. The hydroxytyrosol composition can improve the contents of collagen, hydroxyproline and TGF-beta1 and promote ECM synthesis and skin repair; mMP-1 expression is inhibited, and collagen degradation is reduced; the MDA level is reduced, and the oxidation resistance is enhanced; meanwhile, the moisture content and the hyaluronic acid content of the skin are increased, the moisturizing performance is improved, the components are definite, the quality is controllable, skin aging can be delayed in a multi-target mode, and good application prospects are achieved in the anti-aging field.

Description

Technical Field

[0001] This invention belongs to the field of nutritional compositions and cosmetics technology, specifically relating to a hydroxytyrosol composition and its application in anti-aging products. Background Technology

[0002] Skin aging is the result of the combined effects of endogenous physiological aging and exogenous environmental stimuli. Among these, photoaging caused by ultraviolet (UVB) radiation is the most significant exogenous factor. UVB induces oxidative stress, damages the collagen network, and abnormally activates matrix metalloproteinases, leading to decreased skin hydration, reduced elasticity, increased wrinkles, and impaired repair capabilities, severely impacting skin health and appearance. Therefore, developing anti-aging products that specifically combat UVB damage and possess both antioxidant and collagen-repairing functions has become a research hotspot in the fields of nutritional compositions and cosmetics.

[0003] Various anti-aging compositions have emerged in the prior art. For example, patent CN121313696A discloses an endogenous anti-aging composition based on an internal-external synergistic mechanism and its preparation method. This endogenous anti-aging composition includes: α-ketoglutarate calcium, olive leaf extract, nicotinic acid, pyrrolidinequinoline quinone, pomegranate extract, and coenzyme Q10. In the olive leaf extract, the mass content of hydroxytyrosol ranges from 10% to 20%, attempting to achieve multidimensional anti-aging through multi-pathway synergy. However, this type of composition has significant shortcomings: First, its composition is complex, considering multiple dimensions of anti-aging needs such as bone density and ovarian function, but it does not focus on the core pathological mechanism of skin photoaging, resulting in weak anti-aging targeting. Second, the origin, place of origin, and extraction process of the plant extracts are not clearly defined, lacking unified quality control standards, leading to fluctuations in the content of core active ingredients such as hydroxytyrosol, affecting the stability and reliability of product efficacy. Third, efficacy verification relies on subjective questionnaire assessment, and a systematic detection system based on objective biomarkers has not been established, limiting its reference value.

[0004] Furthermore, single-ingredient anti-aging products suffer from the problem of targeting only a single point of action: while pyrroloquinoline quinone can regulate mitochondrial function and reduce reactive oxygen species production, its effect on promoting collagen synthesis is limited; hydroxytyrosol possesses antioxidant and anti-inflammatory activities, but lacks effective inhibition of matrix metalloproteinases, making it difficult to comprehensively address the multiple damages caused by photoaging of the skin. Moreover, current technologies have not yet clarified the synergistic anti-aging effects of pyrroloquinoline quinone and hydroxytyrosol, nor have they explored the optimal ratio between the two, failing to fully leverage the complementary advantages between the ingredients and hindering the achievement of highly efficient and comprehensive anti-aging effects.

[0005] Based on this, developing a hydroxytyrosol composition with clearly defined ingredients, scientifically proportioned ingredients, controllable quality, and verifiable efficacy against UVB-induced photoaging through objective indicators is of great significance for improving the targeting and reliability of anti-aging products, and also meets the current market demand for efficient and safe anti-aging products. Summary of the Invention

[0006] To address the above shortcomings, the present invention provides a hydroxytyrosol composition and its application in anti-aging products.

[0007] the term:

[0008] In this invention, the term pyrroloquinoline quinone, abbreviated as PQQ, has the chemical name 4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid, and the molecular formula is C0. 14 H6N2O8, with a molecular weight of 334.21, is a red to orange-red crystalline powder. It is highly water-soluble and slightly soluble in organic solvents such as methanol and ethanol. It possesses biological activities including regulating mitochondrial function, scavenging reactive oxygen species, antioxidation, and promoting cell proliferation and repair. It is one of the core active ingredients of the composition of this invention. This invention does not specifically limit the source of pyrroloquinoline quinone; it can be obtained through conventional preparation methods in the art, such as chemical synthesis and microbial fermentation. Regardless of the preparation process, as long as its chemical structure is consistent with the above definition of pyrroloquinoline quinone, it falls within the scope of pyrroloquinoline quinone referred to in this invention.

[0009] In this invention, the term hydroxytyrosol is used, with the English name Hydroxytyrosol and the chemical name 2-(3,4-dihydroxyphenyl)ethanol, and the molecular formula C8H12H2O. 10 O3, with a molecular weight of 154.16, is a pale yellow to light brown liquid or white crystalline powder. It is readily soluble in polar solvents such as water, ethanol, and propylene glycol, but sparingly soluble in non-polar solvents. It possesses strong free radical scavenging ability, antioxidant, anti-inflammatory, and skin barrier protective bioactivity, and is one of the core active ingredients of the composition of this invention. This invention does not specifically limit the source of hydroxytyrosol. It can be extracted from natural plant materials such as olive leaves and olive pomace, or obtained through conventional preparation methods in the art, such as chemical synthesis and biotransformation. Regardless of the extraction raw material or preparation process, as long as its chemical structure is consistent with the above definition of hydroxytyrosol, it falls within the scope of hydroxytyrosol referred to in this invention.

[0010] The technical solution of this invention is as follows: On one hand, the present invention provides a hydroxytyrosol composition, wherein the hydroxytyrosol composition comprises pyrrolquinone and hydroxytyrosol.

[0011] Specifically, the weight ratio of pyrroloquinoline quinone to hydroxytyrosol is 1-20:1-5.

[0012] More specifically, the weight ratio of pyrroloquinoline quinone to hydroxytyrosol is 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19 or 19-20: 1-2, 2-3, 3-4 or 4-5.

[0013] Preferably, the weight ratio of pyrroloquinoline quinone to hydroxytyrosol is 1-2, 2-3, or 3-4:2-3, 3-4, or 4-5.

[0014] More preferably, the weight ratio of pyrroloquinoline quinone to hydroxytyrosol is 2-3 or 3-4:2-3.

[0015] More preferably, the weight ratio of pyrroloquinoline quinone to hydroxytyrosol is 4:3.

[0016] In another aspect, the present invention provides a method for preparing the hydroxytyrosol composition according to any one of the above claims, the method comprising mixing pyrroloquinoline quinone and hydroxytyrosol uniformly in a weight ratio.

[0017] In another aspect, the present invention provides a product comprising the hydroxytyrosol composition described in any of the preceding claims.

[0018] Specifically, the products mentioned include any one or more of the following: food, health products, pharmaceuticals, and cosmetics.

[0019] Specifically, the products also include excipients acceptable in the food, health product, pharmaceutical, or cosmetic fields.

[0020] Preferably, the excipients acceptable in the food or health product field include, but are not limited to, any one or more of the following: gelling agents, sweeteners, acidulants, humectants, food flavorings, nutritional supplements, thickeners, emulsifiers, and dispersants.

[0021] Preferably, the pharmaceutically acceptable excipients include, but are not limited to: solvents, diluents, disintegrants, precipitation inhibitors, surfactants, flow aids, binders, lubricants, dispersants, suspending agents, isotonic agents, thickeners, emulsifiers, preservatives, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, flavorings, sweeteners, ion exchangers, release agents, coating agents, flavoring agents, or antioxidants.

[0022] Preferably, the cosmetic excipients acceptable in the cosmetic field include, but are not limited to, one or more of the following: moisturizers, thickeners, emollients, skin conditioning agents, emulsifiers, preservatives, softeners, lubricants, and stabilizers.

[0023] Specifically, the food or health product also includes nutritionally acceptable nutrients.

[0024] Preferably, the nutritional additives include, but are not limited to, any one or more of the following: dietary fiber, prebiotics, protein, lipids, minerals, and vitamins.

[0025] Preferably, the dosage form of the food or health product includes any one or more of solid dosage forms, semi-solid dosage forms, and liquid dosage forms.

[0026] Preferably, the dosage form of the medicine includes any one or more of the following: tablets, pills, powders, suspensions, gels, emulsions, creams, granules, capsules, suppositories, injections, sprays, and injections.

[0027] Preferably, the cosmetics include, but are not limited to, any one or more of the following: face cream, face mask, eye cream, neck cream, hand cream, body lotion, moisturizing lotion, serum, toner, shampoo, conditioner, shower gel, or facial cleanser.

[0028] In another aspect, the present invention provides the use of the hydroxytyrosol composition described in any one of the above claims in the preparation of any one or more of the following products: (1) Foods or health products that help with anti-oxidation or improve skin hydration; (2) Anti-aging, skin hydration improvement, anti-inflammatory or antioxidant drugs; (3) Cosmetics that are anti-aging, hydrating, moisturizing, anti-inflammatory or antioxidant.

[0029] In another aspect, the present invention provides a method that helps to resist oxidation or improve skin hydration, the method comprising using any of the hydroxytyrosol compositions or health products described above.

[0030] Specifically, the method includes administering an effective amount of a hydroxytyrosol composition or health supplement to the subject.

[0031] Preferably, the subject is a mammal.

[0032] More preferably, the subject is a human being.

[0033] In another aspect, the present invention provides a method for anti-aging, hydrating, moisturizing, anti-inflammatory or antioxidant effects, the method comprising using any of the hydroxytyrosol compositions or cosmetics described above.

[0034] Specifically, the method includes administering an effective amount of a hydroxytyrosol composition or cosmetic to the subject.

[0035] Preferably, the subject is a mammal.

[0036] More preferably, the subject is a human being.

[0037] In another aspect, the present invention provides a method for anti-aging, hydrating, moisturizing, anti-inflammatory or antioxidant purposes, the method comprising using any of the hydroxytyrosol compositions or pharmaceuticals described above.

[0038] Specifically, the method includes administering an effective amount of a hydroxytyrosol composition or drug to the subject.

[0039] Preferably, the subject is a mammal.

[0040] More preferably, the subject is a human being.

[0041] The beneficial effects of this invention are as follows: This invention relates to a hydroxytyrosol composition composed of pyrrolquinone and hydroxytyrosol. The extracellular matrix (ECM) is the core foundation for maintaining skin structure and morphology; collagen is a core component of the ECM, and hydroxyproline is its characteristic amino acid. TGF-β1 and MMP-1, as key factors in aging-related secretory phenotypes, regulate ECM remodeling and skin aging. This hydroxytyrosol composition can increase the levels of collagen, hydroxyproline, and TGF-β1, promoting ECM synthesis and skin repair; inhibit MMP-1 expression, reducing collagen degradation; lower MDA levels, enhancing antioxidant capacity; and simultaneously increase skin hydration and hyaluronic acid content, improving moisturizing performance. Its components are clearly defined and its quality is controllable. It can delay skin aging through multiple targets and has promising application prospects in the anti-aging field. Attached Figure Description

[0042] Figure 1 This represents the Col I content in skin tissue; compared to the blank control group, the figure shows... p<0.001, p < 0.0001; compared with the model group, #p < 0.05, ###p < 0.001, ####p < 0.0001; compared with Comparative Example 1, $$p < 0.01, $$$$p < 0.0001; compared with Comparative Example 2, &p < 0.05, &&p < 0.01, &&&p < 0.001.

[0043] Figure 2The figures show the levels of Col III, Col IV, Col VII, and Col 17 in skin tissue; compared to the blank control group, p<0.05, p<0.001, p<0.0001; compared with the model group, ##p<0.01, ####p<0.0001.

[0044] Figure 3 The figure shows the MMP-1 content in skin tissue; compared with the blank control group, p<0.05, p<0.01; compared with the model group, ###p<0.001, ####p<0.0001.

[0045] Figure 4 The figure shows the hydroxyproline content in skin tissue; compared with the blank control group, p<0.05; compared with the model group, #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001; compared with Comparative Example 1, $p<0.05, $$p<0.01; compared with Comparative Example 2, &p<0.05.

[0046] Figure 5 The figure shows the expression level of TGF-β1 in skin tissue; compared with the blank control group, p<0.05, p<0.001, p < 0.0001; compared with the model group, ##p < 0.01, ####p < 0.0001; compared with Comparative Example 1, $$p < 0.01, $$$p < 0.001, $$$$p < 0.0001; compared with Comparative Example 2, &p < 0.05, &&p < 0.01.

[0047] Figure 6 The results show the measurement results of moisture-related indicators; compared with the blank control group, the figure shows... p<0.05, p<0.01, p < 0.0001; compared with the model group, ##p < 0.01, ####p < 0.0001; compared with Comparative Example 1, $$p < 0.01, $$$p < 0.001, $$$$p < 0.0001; compared with Comparative Example 2, &p < 0.05, &&p < 0.01, &&&&p < 0.0001.

[0048] Figure 7 This represents the MDA level in skin tissue; compared to the blank control group, the figure shows... p<0.001, p < 0.0001; compared with the model group, ##p < 0.01, ####p < 0.0001; compared with Comparative Example 1, $p < 0.05, $$p < 0.001, $$$$p < 0.0001; compared with Comparative Example 2, &&p < 0.01, &&&p < 0.001. Detailed Implementation

[0049] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0050] The present invention will be further described below by way of specific embodiments. All instruments, devices, equipment, reagents, products, etc., used in the embodiments of the present invention were obtained through conventional commercial channels unless otherwise specified. The olive leaf extract used in Comparative Example 5 of the present invention was purchased from Bolise, and the pomegranate extract was purchased from Jiangsu Caiwei Biotechnology Co., Ltd.

[0051] Examples 1-4 Examples 1-4 of this invention provide a composition comprising pyrroloquinoline quinone and hydroxytyrosol. The weight ratios of pyrroloquinoline quinone and hydroxytyrosol in the composition are shown in Table 1. The preparation method is to mix pyrroloquinoline quinone and hydroxytyrosol evenly according to the weight ratio.

[0052] Table 1

[0053] Comparative Example 1: Ergothioneine A single component, pyrroloquinoline quinone, was used as Comparative Example 1.

[0054] Comparative Example 2 Hydroxytyrosol Single-component hydroxytyrosol, as comparative example 2.

[0055] Comparative Example 3: A composition A composition comprising pyrroloquinoline quinone and nicotinic acid, wherein the weight ratio of pyrroloquinoline quinone to nicotinic acid in the composition is 4:3. The composition is prepared by uniformly mixing pyrroloquinoline quinone and nicotinic acid according to the weight ratio.

[0056] Comparative Example 4: A composition A composition comprising pyrroloquinoline quinone and nicotinamide, wherein the ratio of pyrroloquinoline quinone to calcium α-ketoglutarate is 4:3. The composition is prepared by uniformly mixing pyrroloquinoline quinone and calcium α-ketoglutarate according to the weight ratio.

[0057] Comparative Example 5 The composition was prepared according to Example 1 of patent CN121313696A. The composition consists of 100 parts olive leaf extract, 10 parts nicotinic acid, 10 parts pyrroloquinoline quinone, 0.0006 parts pomegranate extract, 0.0016 parts coenzyme Q10, and 200 parts calcium α-ketoglutarate. The preparation method is to mix the above raw materials.

[0058] Experimental Example 1: Verification of the efficacy of the composition 1. Grouping and feeding of animals Animal experiments were conducted strictly in accordance with the Guidelines for the Management and Use of Laboratory Animals of the Animal Experiment Center of South China Agricultural University. Seventy-two SPF-grade female BALB / c nude mice, weighing 20±2g and aged 8 weeks, were housed in the SPF-grade Animal Experiment Center of South China Agricultural University. The mice were housed in a standardized SPF-grade animal room with a relative humidity of 55-70%, an ambient temperature of 25±2℃, and a 12-hour diurnal cycle. After a week of acclimatization feeding before the formal experiments, the mice were randomly divided into a blank control group (6 mice) and an experimental group (66 mice). The experimental groups included: a model group, a glutathione positive control group, Example 1-Example 4 groups, and Comparative Examples 1-Comparative Examples 5 groups.

[0059] From week 1 to week 6, nude mice in each group were administered gavage daily according to Table 1: Table 1

[0060] From week 1 to week 6, while administering oral gavage to nude mice, all groups except the control group received UVB irradiation on their backs. Irradiation was performed on Mondays, Wednesdays, Fridays, and Sundays, for a total of four times per week. The irradiation method was as follows: after oral gavage, the mice were placed in a restraint device with their backs facing upwards under a UVB lamp. The lamp was preheated for 30 minutes before each irradiation session. The UVB lamp wavelength was 313 nm, and the lamp was positioned 20 cm above the mouse's back. The irradiation power was measured using a dosimeter. The irradiation dose was 200 mJ / cm² in weeks 1-2. 2 Week 2-3: 300 mJ / cm 2 Weeks 3-6: 400 mJ / cm 2 .

[0061] 2. Analysis of relevant indicators After week 6, mice were euthanized by cervical dislocation after a 12-hour fast. The mice were dissected, and skin tissue from the UVB-irradiated area on the back was harvested. Subcutaneous fat and connective tissue were scraped off, and the tissue was rinsed twice with pre-cooled physiological saline, dried, and frozen at -80°C. Preparation of 10% skin tissue homogenate: Nine times the weight of the skin tissue in pre-cooled physiological saline was measured. Two-thirds of the saline solution was poured into a small beaker containing tissue fragments, which were then cut into small pieces and poured into a homogenizing tube. The remaining one-third of the saline solution was used to rinse the beaker walls. A 10% tissue homogenate was then prepared using a tissue homogenizer.

[0062] 2.1 Determination of Col I content The Col I content in skin tissue was detected using a kit method. 0.1 g of back skin was added to 0.9 mL of pre-cooled PBS, and the mixture was thoroughly homogenized to obtain a 10% tissue homogenate. The homogenate was centrifuged at 3000 rpm and 4°C for 15 min. The corresponding collagen content was determined according to the Col I kit instructions. The results are shown in Table 2 and... Figure 1 As shown.

[0063] Table 2

[0064] Compared with the blank control group, the Col I content in the skin tissue of the model group was significantly reduced, indicating that successful modeling led to a decrease in Col I synthesis. All example groups significantly increased the Col I content in the skin tissue, and the levels were much higher than those in the blank control group and the positive control group, with the best effect observed in Example 1 group.

[0065] The contents of Col III, Col IV, Col VII, and Col 17 in skin tissues of the blank control group, model control group, positive control group, and the combination of Example 1 were detected using a kit method. The results are shown in Table 3 and... Figure 2 As shown.

[0066] Table 3

[0067] 2.2 Determination of matrix metalloproteinase-1 (MMP-1) content The MMP-1 content in skin tissue was detected using a kit method. 0.1 g of back skin was added to 0.9 mL of pre-cooled PBS, and the mixture was thoroughly homogenized to obtain a 10% tissue homogenate. The homogenate was centrifuged at 3000 r / min and 4℃ for 15 min. The supernatant was then used to determine the MMP-1 content according to the kit instructions.

[0068] The measurement results are shown in Table 4 and Figure 3 As shown.

[0069] Table 4

[0070] Inhibiting the activity or expression of MMP-1 can reduce collagen breakdown, maintain the integrity and elasticity of skin tissue, and is of great significance for delaying skin aging and repairing skin damage. The hydroxytyrosol composition of the present invention can significantly reduce MMP-1 content, and the effect is better than that of the positive control group.

[0071] 2.3 Determination of hydroxyproline content The hydroxyproline content in skin tissue was determined using a kit method. 100 mg of the treated skin was minced and added to 1 mL of hydrolysate. The mixture was heated at 95°C for 15 min, and the hydroxyproline content was determined according to the kit instructions. The results are shown in Table 5. Figure 4 As shown.

[0072] Table 5

[0073] Hydroxyproline is an amino acid unique to collagen, and its content is positively correlated with the total amount of collagen in skin tissue. Therefore, the detection value of hydroxyproline can directly reflect the level and content of collagen synthesis in the skin. The hydroxytyrosol composition of the present invention can significantly increase the hydroxyproline content in the skin.

[0074] 2.4 Determination of TGF-β1 expression The expression level of TGF-β1 in skin tissue was detected using a kit method. After washing, mincing, and grinding the tissue to obtain a homogenate, centrifuged at 5000g for 5 min with a radius of 10 cm, and the supernatant was collected for detection. Standard wells and sample wells were set up. Horseradish peroxidase (HRP)-labeled detection antibody was added to the standard and sample wells, and the mixture was incubated at a constant temperature. After repeated washing, substrate and stop solution were added, and the OD value of each well was measured at 450 nm. The sample concentration of TGF-β1 in each group was detected. The results are shown in Table 6. Figure 5As shown.

[0075] Table 6

[0076] TGF-β1 is a multifunctional cytokine that plays a key regulatory role in skin tissue repair, fibrosis, and collagen synthesis. Compared with the blank control group, the expression level of TGF-β1 in the skin tissue of the model group was significantly reduced. The hydroxytyrosol composition of this invention can effectively increase the expression level of TGF-β1.

[0077] 2.5 Determination of Moisture-Related Indicators (1) Skin moisture content Take a 1cm area and weigh it for wet weight; bake it in an oven at 80℃ for 12 hours and weigh it for dry weight. Skin moisture percentage (%) = (wet weight - dry weight) / wet weight 100%.

[0078] (2) Hyaluronic acid (HA) content Take 0.1g of back skin and add 0.9mL of pre-cooled PBS. After thorough grinding, obtain a 10% tissue homogenate. Centrifuge at 3000r / min and 4℃ for 15min. Determine the HA content according to the kit instructions.

[0079] The measurement results are shown in Table 7 and Figure 6 As shown.

[0080] Table 7

[0081] The skin water percentage and HA content in the model group were significantly lower than those in the blank control group, suggesting that reduced HA synthesis in the skin is a significant reason for the decreased skin water retention capacity. Each example group exhibited the best HA synthesis promotion and skin water retention effects, demonstrating superior skin moisturizing effects compared to the control group.

[0082] 2.6 MDA level 0.1g of back skin was added to 0.9mL of pre-cooled PBS, and the mixture was thoroughly homogenized to obtain a 10% tissue homogenate. The homogenate was centrifuged at 3000 rpm and 4℃ for 15 min, and the MDA level of the skin tissue was detected according to the ELISA kit instructions. The results are shown in Table 8. Figure 7 As shown.

[0083] Table 8

[0084] MDA is the end product of lipid peroxidation. Its content in tissues directly reflects the degree of lipid peroxidation and indirectly reflects the degree of damage to cells by free radicals. The hydroxytyrosol composition of this invention can effectively reduce MDA levels, indicating that it has significant antioxidant activity. It can reduce oxidative damage to skin cells and biomolecules by free radicals by inhibiting lipid peroxidation in skin tissue.

[0085] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A hydroxytyrosol composition, characterized in that, The hydroxytyrosol composition consists of pyrroloquinoline quinone and hydroxytyrosol.

2. The hydroxytyrosol composition according to claim 1, characterized in that, The weight ratio of pyrroloquinoline quinone to hydroxytyrosol is 1-20:1-5.

3. The hydroxytyrosol composition according to claim 2, characterized in that, The weight ratio of pyrroloquinoline quinone to hydroxytyrosol is 1-4:2-5.

4. A method for preparing the hydroxytyrosol composition according to any one of claims 1-3, characterized in that, The preparation method includes mixing pyrroloquinoline quinone and hydroxytyrosol in a uniform weight ratio.

5. A product characterized in that, The product comprises the hydroxytyrosol composition according to any one of claims 1-3.

6. The product according to claim 5, characterized in that, The products mentioned include any one or more of the following: food, health products, pharmaceuticals, and cosmetics.

7. The product according to claim 5, characterized in that, The products also include excipients acceptable in the food, health product, pharmaceutical, or cosmetic fields.

8. The product according to claim 6, characterized in that, The food or health product mentioned also includes nutritionally acceptable nutrients.

9. The product according to claim 6, characterized in that, The dosage forms of the food or health products mentioned include solid dosage forms, semi-solid dosage forms, or liquid dosage forms.

10. The product according to claim 6, characterized in that, The dosage forms of the medicine include any one or more of the following: tablets, pills, powders, suspensions, gels, emulsions, creams, granules, capsules, suppositories, injections, sprays, and injections.

11. The product according to claim 6, characterized in that, The cosmetics mentioned include any one or more of the following: face cream, face mask, eye cream, neck cream, hand cream, body lotion, moisturizer, serum, toner, shampoo, conditioner, shower gel, or facial cleanser.

12. The use of the hydroxytyrosol composition according to any one of claims 1-3 in the preparation of a product, characterized in that, The products mentioned include any one or more of the following: (1) Foods or health products that help with anti-oxidation or improve skin hydration; (2) Anti-aging, skin hydration improvement, anti-inflammatory or antioxidant drugs; (3) Cosmetics that are anti-aging, hydrating, moisturizing, anti-inflammatory or antioxidant.

Images